Search Results for: Nuovi farmaci promettenti contro l’Alzheimer

Caldo, afa? Anche i farmaci “soffrono”. Ma cosa accade davvero ai medicinali quando le temperature schizzano così in alto come in questi giorni?Disattenzioni come lasciare una medicina in macchina o…

Il vademecum di Aifa per i medicinali in valigia

Aifa, attenzione a quelli per ansia e ipertensione

Limitate alterazioni metaboliche indotte da farmaci psichiatrici

Per l’uso innovativo dell’IA nella scoperta di farmaci e vaccini

A Bergamo tornano presto ad accendersi i riflettori sulla Sanità che cambia pelle tra bisogni di salute sempre più impellenti e una governance da rivedere per gestire la spinta di…

Farmaci e vaccini sono al primo posto in Italia per surplus con l’estero, con oltre 21 miliardi di attivo nel 2024, mentre i nuovi record di produzione (56 miliardi) ed…

In Olanda è già adottato per guidare la prescrizione dei farmaci e anche in Italia cresce l’interesse per la farmacogenetica, che può prevenire effetti collaterali e fallimenti terapeutici

Delirium affects one-third of hospitalized older adults and is associated with prolonged length of stay, institutional discharge, long-term functional and cognitive decline, Alzheimer disease and related dementias (AD/ADRD), and death. Moreover, the costs of delirium exceed $182 billion annually in the US alone. Despite these compelling data, accurate identification of delirium remains challenging, with more than half of delirium going unrecognized in routine care. While delirium prevention has advanced substantially, delirium treatment, which relies on early and accurate identification, lags. More than 40 tools are available for delirium assessment, ranging from short structured screens to in-depth reference standards. Evidence on how to implement these tools to improve delirium identification at the bedside, including which tool to use, who should administer it, how often, and how to educate and engage the care team, remains limited.

This Viewpoint examines the use of blood-based biomarkers to test for Alzheimer disease and outlines why they should not be the first or only tool used in screening for cognitive impairment.

This Special Communication presents a framework for using a cross-species behavioral neuroscience approach to study emotional well-being and brain aging in the context of Alzheimer disease and related dementias.

Buildup of the protein amyloid β (Aβ) in the brain can predict Alzheimer disease years before symptoms appear. Although learning about the risk may relieve some anxiety, a new study suggests that it lessens individuals’ motivation to maintain a healthy lifestyle.